With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a clinical study ...

Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target Published first on TheFly – the ultimate ...